Study to Test the Safety and Immunogenicity of VARIVAX (2007 Process) (Study V210-057) (Completed)

Safety, Tolerability, and Immunogenicity of VARIVAX (2007 Commercial VZV Bulk Process) Administered Concomitantly With M-M-R II in Healthy Children 12-to-23 Months of Age

This study will test the safety, tolerability, and immunogenicity of VARIVAX manufactured with the 2007 commercial Varicella-Zoster Virus (VZV) bulk process when concomitantly administered with M-M-R II in healthy children.

This treatment has been approved for sale to the public.

Inclusion Criteria:

• Subject is in good health based on medical history
• Subject has no history of measles, mumps, rubella, chickenpox, or shingles

Exclusion Criteria:

• Subject has previously received measles, mumps, rubella, and/or varicella vaccine either alone or in combination
• Subject has history of immune disorders
• Subject has been exposed to chickenpox/shingles, measles, mumps, rubella or varicella within 4 weeks of study start
• Subject has received an inactivated vaccine within 14 days of first dose of study vaccine
• Subject has received a live vaccine within 30 days of first dose of study vaccine
• Subject has received a blood transfusion or blood-derived products within 3 months of receiving study vaccine
• Subject has had a fever within 72 hours of study start